Company intelligence / Profile preview
DreamTec
- Ownership
- Public · A192650
- Development stage
- Other
Overview
DreamTec has developed a novel oral COVID‑19 vaccine using genetically engineered Bacillus subtilis spores displaying the SARS-CoV‑2 spike protein receptor-binding domain. Pilot studies in healthy volunteers showed increased neutralizing antibody levels after administration. Preclinical animal data indicated no alarming side effects and induction of IgG/IgM antibodies. The product aims to be stable at room temperature for up to six months and easy to administer orally; Phase I trials are planned or imminent as of the latest reports.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Recombinant proteinRNA therapyStem cell therapyExosome-based therapyMicrobial therapy3D bioprinting
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Financials
- Market cap
- $29.3B
- Total revenue
- $6.5B
- Enterprise value
- $45.1B
Beyond the preview
Go deeper on DreamTec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DreamTec.